Prothena Corporation PLC
PRTA
查看详细走势图
8.910USD
+0.560+6.71%
收盘 02/06, 16:00（美东）报价延迟15分钟
479.63M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.71%
5天
+1.14%
1月
-2.41%
6月
+15.41%
今年开始到现在
-6.70%
1年
-36.58%
查看详细走势图
TradingKey Prothena Corporation PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Prothena Corporation PLC当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名98/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价20.33。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Prothena Corporation PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Prothena Corporation PLC亮点
亮点风险
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
业绩高增长
公司营业收入稳步增长，连续3年增长150.73%
估值高估
公司最新PE估值-1.71，处于3年历史高位
机构减仓
最新机构持股43.29M股，环比减少31.62%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值2.14M
分析师目标
根据
7
位分析师
持有
评级
20.333
目标均价
+128.72%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Prothena Corporation PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Prothena Corporation PLC简介
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
公司代码PRTA
公司Prothena Corporation PLC
CEOKinney (Gene G)
网址https://www.prothena.com/
相关品种
